{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T05:00:15Z","timestamp":1782190815934,"version":"3.54.5"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The significant morbidity and mortality resulted from the infection of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) call for urgent development of effective and safe vaccines. We report the immunogenicity and safety of an inactivated SARS-CoV-2 vaccine, KCONVAC, in healthy adults.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Phase 1 and phase 2 randomized, double-blind, and placebo-controlled trials of KCONVAC were conducted in healthy Chinese adults aged 18 to 59 years. The participants in the phase 1 trial were randomized to receive two doses, one each on Days 0 and 14, of either KCONVAC (5 or 10 \u03bcg\/dose) or placebo. The participants in the phase 2 trial were randomized to receive either KCONVAC (at 5 or 10 \u03bcg\/dose) or placebo on Days 0 and 14 (0\/14 regimen) or Days 0 and 28 (0\/28 regimen). In the phase 1 trial, the primary safety endpoint was the proportion of participants experiencing adverse reactions\/events within 28 days following the administration of each dose. In the phase 2 trial, the primary immunogenicity endpoints were neutralization antibody seroconversion and titer and anti-receptor-binding domain immunoglobulin G seroconversion at 28 days after the second dose.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>In the phase 1 trial, 60 participants were enrolled and received at least one dose of 5-\u03bcg vaccine (<jats:italic toggle=\"yes\">n<\/jats:italic>\u200a=\u200a24), 10-\u03bcg vaccine (<jats:italic toggle=\"yes\">n<\/jats:italic>\u200a=\u200a24), or placebo (<jats:italic toggle=\"yes\">n<\/jats:italic>\u200a=\u200a12). In the phase 2 trial, 500 participants were enrolled and received at least one dose of 5-\u03bcg vaccine (<jats:italic toggle=\"yes\">n<\/jats:italic>\u200a=\u200a100 for 0\/14 or 0\/28 regimens), 10-\u03bcg vaccine (<jats:italic toggle=\"yes\">n<\/jats:italic>\u200a=\u200a100 for each regimen), or placebo (<jats:italic toggle=\"yes\">n<\/jats:italic>\u200a=\u200a50 for each regimen). In the phase 1 trial, 13 (54%), 11 (46%), and seven (7\/12) participants reported at least one adverse event (AE) after receiving 5-, 10-\u03bcg vaccine, or placebo, respectively. In the phase 2 trial, 16 (16%), 19 (19%), and nine (18%) 0\/14-regimen participants reported at least one AE after receiving 5-, 10-\u03bcg vaccine, or placebo, respectively. Similar AE incidences were observed in the three 0\/28-regimen treatment groups. No AEs with an intensity of grade 3+ were reported, expect for one vaccine-unrelated serious AE (foot fracture) reported in the phase 1 trial. KCONVAC induced significant antibody responses; 0\/28 regimen showed a higher immune responses than that did 0\/14 regimen after receiving two vaccine doses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Both doses of KCONVAC are well tolerated and able to induce robust immune responses in healthy adults. These results support testing 5-\u03bcg vaccine in the 0\/28 regimen in an upcoming phase 3 efficacy trial.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial Registration:<\/jats:title>\n            <jats:p>\n                                 http:\/\/www.chictr.org.cn\/index.aspx (No. ChiCTR2000038804, http:\/\/www.chictr.org.cn\/showproj.aspx?proj=62350; No. ChiCTR2000039462, http:\/\/www.chictr.org.cn\/showproj.aspx?proj=63353).<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cm9.0000000000001573","type":"journal-article","created":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T14:38:35Z","timestamp":1619793515000},"page":"1289-1298","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":53,"title":["Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials"],"prefix":"10.1097","volume":"134","author":[{"given":"Hong-Xing","family":"Pan","sequence":"first","affiliation":[{"name":"NHC Key Laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention), Nanjing, Jiangsu 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Kai","family":"Liu","sequence":"additional","affiliation":[{"name":"Shenzhen Kangtai Biological Products Co., Ltd., Shenzhen, Guangdong 518057, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao-Ying","family":"Huang","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-Fan","family":"Li","sequence":"additional","affiliation":[{"name":"Beijing Minhai Biological Technology Co., Ltd., Beijing 102600, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Yun","family":"Chang","sequence":"additional","affiliation":[{"name":"Beijing Minhai Biological Technology Co., Ltd., Beijing 102600, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Fei","family":"Liu","sequence":"additional","affiliation":[{"name":"Beijing Minhai Biological Technology Co., Ltd., Beijing 102600, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Ling","family":"Wang","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Chu","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention), Nanjing, Jiangsu 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Lei","family":"Hu","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention), Nanjing, Jiangsu 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Xin","family":"Li","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention), Nanjing, Jiangsu 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Dan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Huaiyin District Center for Disease Control and Prevention, Huai\u2019an, Jiangsu 223003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Liang","family":"Wu","sequence":"additional","affiliation":[{"name":"Huaiyin District Center for Disease Control and Prevention, Huai\u2019an, Jiangsu 223003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yu","family":"Xu","sequence":"additional","affiliation":[{"name":"Vazyme Biotech Co., Ltd, Nanjing, Jiangsu 210000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[{"name":"National Institutes for Food and Drug Control, Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Wang","sequence":"additional","affiliation":[{"name":"National Institutes for Food and Drug Control, Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jie","family":"Tan","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Jin","family":"Huang","sequence":"additional","affiliation":[{"name":"National Institutes for Food and Drug Control, Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Cai","family":"Zhu","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention), Nanjing, Jiangsu 210009, China"},{"name":"Center for Global Health, Nanjing Medical University, Nanjing, Jiangsu 211166, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,6,5]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jama.2020.15543","article-title":"Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials","volume":"324","author":"Xia","year":"2020","journal-title":"JAMA"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Zhang","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2020","journal-title":"Lancet"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 \u2013 preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N Engl J Med"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1016\/j.vaccine.2014.02.094","article-title":"Immune response to hepatitis B vaccine with high antigen content in non-responders after standard primary vaccination in Chinese adults","volume":"32","author":"Pan","year":"2014","journal-title":"Vaccine"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1080\/22221751.2020.1743767","article-title":"Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2","volume":"9","author":"Nie","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/oxfordjournals.aje.a115009","article-title":"Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines","volume":"128","author":"McBean","year":"1988","journal-title":"Am J Epidemiol"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1053\/j.ajkd.2004.03.029","article-title":"Evaluation of T helper-1\/-2 balance on the basis of IgG subclasses and serum cytokines in children with glomerulonephritis","volume":"44","author":"Kawasaki","year":"2004","journal-title":"Am J Kidney Dis"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000001573","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T20:26:48Z","timestamp":1748982408000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000001573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,28]]},"references-count":17,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000001573","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,28]]}}}